BioLife Solutions Financial Overview for Q3 2025 Set for November
BioLife Solutions to Announce Q3 2025 Financial Results
BioLife Solutions, Inc. (NASDAQ: BLFS), a pioneering developer in bioproduction products and services for the cell and gene therapy sector, will report its financial results for the third quarter of 2025. The announcement is set to occur following the market close on November 6, 2025. This report comes as the company continues to make strides in the biopharmaceutical industry.
Conference Call and Webcast Details
The company plans to host a conference call and live webcast at 4:30 PM ET the same day. This session will provide an opportunity for management to offer insight into the financial results, alongside a general business update to summarize recent developments.
Accessing the Webcast
Investors can log on to the Investor Relations section of BioLife Solutions' website to access the webcast. The call will also be available by dialing a toll-free number that will facilitate participation from both domestic and international callers. Additionally, a replay of the webcast will be accessible approximately two hours after the call concludes, with an archive lasting 90 days.
About BioLife Solutions, Inc.
As a leader in the bioproduction field, BioLife Solutions focuses on supplying products that ensure the safe handling and distribution of biologic materials. Their expertise is crucial to the commercialization of new therapies within the broader biopharma spectrum. The company prides itself on providing solutions that preserve the integrity of biologic products during collection, development, and storage.
Contact Information
For further inquiries, interested parties can reach out to:
Company Contact
Troy Wichterman
Chief Financial Officer
(425) 402-1400
Email: twichterman@biolifesolutions.com
Investor Relations
Alliance Advisors IR
Jody Cain
(310) 691-7100
Email: jcain@allianceadvisors.com
Frequently Asked Questions
What is the date of the financial results announcement for BioLife Solutions?
The financial results for Q3 2025 will be announced on November 6, 2025.
How can investors participate in the conference call?
Investors can join the call by dialing a toll-free number provided by the company or through the live webcast on their Investor Relations website.
Where can I find the webcast replay?
The replay of the webcast will be available approximately two hours after the call and can be found on the BioLife Solutions Investor Relations page for 90 days.
What sectors does BioLife Solutions serve?
BioLife Solutions primarily serves the cell and gene therapy market, offering essential bioproduction services and solutions.
Who should I contact for inquiries regarding BioLife Solutions?
For company-related inquiries, you can contact Troy Wichterman, Chief Financial Officer, directly at (425) 402-1400 or via email.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.